Longer PFS With Maintenance Rituximab After CVP in FL

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 3
Volume 15
Issue 3

In patients undergoing treatment for follicular lymphoma, (FL) maintenance rituximab (Rituxan) after a cyclophosphamide, vincristine, and prednisone (CVP) regimen appears to confer a survival benefit, Sandra Horning, MD, professor of medicine, Stanford University, said at the 47th Annual Meeting of the American Society of Hematology (abstract 349).

ATLANTA—In patients undergoing treatment for follicular lymphoma, (FL) maintenance rituximab (Rituxan) after a cyclophosphamide, vincristine, and prednisone (CVP) regimen appears to confer a survival benefit, Sandra Horning, MD, professor of medicine, Stanford University, said at the 47th Annual Meeting of the American Society of Hematology (abstract 349).

Dr. Horning and her colleagues in the Eastern Cooperative Oncology Group (ECOG) hypothesized that in patients with indolent lymphoma, chemotherapy induction to maximal benefit followed by rituximab would improve progression-free survival (PFS). "Our initial study design was cyclophosphamide/fludarabine (CF) vs CVP with or without maintenance rituximab," Dr. Horning explained. "However, due to toxicity with the CF regimen, this arm was dropped and the study was revised and repowered in its current form."

Preliminary data from the E1496 study, presented at the American Society of Clinical Oncology meeting in 2004, indicated a superior PFS with maintenance rituximab. In the present analysis, investigators evaluated responses in patients with follicular lymphoma, as they are the dominant subtype in the trial and tend to demonstrate high response rates with rituximab. Of the 304 study patients, 237 had follicular lymphoma (stage III-IV) and were included in this analysis.

After receiving six to eight cycles of CVP (best response plus two additional cycles), patients with follicular lymphoma were randomized to receive maintenance rituximab (375 mg/m2 weekly for 4 weeks) (n = 120) or observation (n = 117). The maintenance regimen was initiated 4 weeks after CVP and repeated every 6 months for 2 years. Dr. Horning noted that the two arms were "overall well-balanced with two exceptions: [patients in] the observation arm tended to be younger, but also were more likely to have 5+ nodal sites."

Follicular Lymphoma Results

Responses to CVP were not significantly different between arms. However, PFS from randomization to maintenance rituximab or observation was significantly longer in the rituximab arm (median PFS, 61 vs 15 months; P < .00001). Maintenance rituximab was associated with a hazard ratio (HR) of 0.40. At 3 years following randomization, the benefit conferred by maintenance rituximab was observed regardless of Follicular Lymphoma International Prognostic Index (FLIPI) score, tumor burden, or presence of residual disease.

Overall survival at 42 months was also significantly superior with maintenance rituximab (91% vs 75% with observation; HR 0.50; P = .03). A subgroup analysis found that maintenance rituximab provided significantly superior overall survival only in patients with a high tumor burden.

Dr. Horning pointed out that "the observation arm exceeded our expectation for overall survival, leading to caution in the use of historical controls in the current analyses of follicular lymphoma. This is consistent with other data that patients with follicular lymphoma are living longer. We anticipate that the majority of patients in this study who failed on the observation arm were able to receive rituximab as a part of their second-line treatment." She also noted that these are the first results that strongly suggest a survival benefit with maintenance rituximab in the initial treatment of follicular lymphoma.

Related Videos
Video 1 - 4 KOLs are featured in "Triaging and Prioritizing Patients with Multiple Myeloma"
Video 1 - 4 KOLs are featured in "CAR T-Cell Therapy: Leukapheresis Practices"
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Overall survival data with blinatumomab in the phase 3 E1910 study may be an “important development” in CD19-positive B-ALL.
Intraoperative radiation therapy may allow surgical and radiation oncologists to collaboratively visualize at-risk areas in patients with cancer.
Positive margin rates have not appeared to improve for patients with cancer undergoing surgical care based on several prior studies.
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Related Content